liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
RUNX1 cooperates with FLT3-ITD to induce leukemia
Leibniz Institute Expt Virol, Germany; Walter and Eliza Hall Institute Medical Research, Australia.
Leibniz Institute Expt Virol, Germany.
Leibniz Institute Expt Virol, Germany; Leibniz Institute Expt Virol, Germany.
Leibniz Institute Expt Virol, Germany.
Show others and affiliations
2017 (English)In: Journal of Experimental Medicine, ISSN 0022-1007, E-ISSN 1540-9538, Vol. 214, no 3, 737-752 p.Article in journal (Refereed) Published
Abstract [en]

Acute myeloid leukemia (AML) is induced by the cooperative action of deregulated genes that perturb self-renewal, proliferation, and differentiation. Internal tandem duplications (ITDs) in the FLT3 receptor tyrosine kinase are common mutations in AML, confer poor prognosis, and stimulate myeloproliferation. AML patient samples with FLT3-ITD express high levels of RUNX1, a transcription factor with known tumor-suppressor function. In this study, to understand this paradox, we investigated the impact of RUNX1 and FLT3-ITD coexpression. FLT3-ITD directly impacts on RUNX1 activity, whereby up-regulated and phosphorylated RUNX1 cooperates with FLT3-ITD to induce AML. Inactivating RUNX1 in tumors releases the differentiation block and down-regulates genes controlling ribosome biogenesis. We identified Hhex as a direct target of RUNX1 and FLT3-ITD stimulation and confirmed high HHEX expression in FLT3-ITD AMLs. HHEX could replace RUNX1 in cooperating with FLT3-ITD to induce AML. These results establish and elucidate the unanticipated oncogenic function of RUNX1 in AML. We predict that blocking RUNX1 activity will greatly enhance current therapeutic approaches using FLT3 inhibitors.

Place, publisher, year, edition, pages
ROCKEFELLER UNIV PRESS , 2017. Vol. 214, no 3, 737-752 p.
National Category
Cell and Molecular Biology
Identifiers
URN: urn:nbn:se:liu:diva-136048DOI: 10.1084/jem.20160927ISI: 000395828600012PubMedID: 28213513OAI: oai:DiVA.org:liu-136048DiVA: diva2:1084866
Note

Funding Agencies|Deutsche Krebshilfe Foundation; Bundesministerium fur Gesundheit; Freie und Hansestadt Hamburg

Available from: 2017-03-27 Created: 2017-03-27 Last updated: 2017-05-23

Open Access in DiVA

fulltext(2573 kB)34 downloads
File information
File name FULLTEXT01.pdfFile size 2573 kBChecksum SHA-512
a6619b0307fa5b79e8e0f4cf950f853ddf2af3347a03632247ae83335a479bd3642b34f62d5c11cbcba5ee7759b97902d5e07c2ca717f4cedb05ef7fb1091b3e
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Cammenga, Jörg
By organisation
Division of Surgery, Orthopedics and OncologyFaculty of Medicine and Health SciencesDepartment of Haematology
In the same journal
Journal of Experimental Medicine
Cell and Molecular Biology

Search outside of DiVA

GoogleGoogle Scholar
Total: 34 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 163 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf